Barr Ellison Solicitors – commercial property
ARM Innovation Hub
Advertisement: Cambridge Network
Advertisement: Mogrify mid banner
Advertisement Cambridge China Centre
Advertisement: CBM
RealVNC mid-banner general
Advertisement EY mid
Advertisement: Bradfield Centre mid
Advertisement: Bridge Fibre mid
Advertisement: Mobas mid banner
RealVNC mid banner careers
Advertisement: RSM
Advertisement: Lynch Wood Park
31 January, 2019 - 09:50 By Tony Quested

Eagle Genomics lands $3.5m to push AI platform into France and US

Cambridge-based Eagle Genomics has secured funding of $3.5 million led by the Environmental Technologies Fund to underpin geographical and technological expansion.

Eagle has developed an AI-powered platform to enable enterprise companies to explore and assess the impact of their products on the microbiome – the ecosystem of bacteria, funghi and viruses present in virtually all living organisms – in relation to human health and the environment.

Commonly used products such as fertilisers, skin creams and detergents are now understood to affect and even modify the microbiome.

The Eagle Genomics platform deploys leading data science, AI and machine learning to reveal new microbiome insight, leading to the development of microbiome-friendly products and assessment of the safety of existing products. 

The new funding will enable Eagle’s expansion into fresh markets to further develop sales and marketing and deepen development capability, accelerating the development of the company’s software platform to meet rapidly growing demand from enterprise companies in the consumer goods, agritech and healthcare industries.

The investment will also support global expansion, with plans to open international offices in Paris and New York to service the European and American markets.

The microbiome, the ecosystem of bacteria, fungi and viruses present in virtually all living organisms, is directly linked with health and is proven to be affected by the products we use and consume. 

The funding round follows the recently announced partnership between Eagle Genomics and Microsoft Genomics, which marked Microsoft’s first venture into the microbiome.

With momentum from this partnership and a significant market opportunity to address, Eagle Genomics is well positioned to revolutionise life sciences R & D.

Eagle Genomics CEO Anthony Finbow (pictured) said: “We are delighted to have secured investment from ETF Partners. Our shared belief that technological innovation is the key to improving human health and the environment will drive us to meet the grand challenges of our age. 

“We look forward to expanding our fantastic team globally to deploy our platform to support our enterprise customers worldwide.”

Robert Genieser, managing partner at ETF Partners, said: “With the unique expertise of the Eagle Genomics team and the technology ecosystem already in place, the company is extremely well placed to enable the exploration of the microbiome at scale.

“From the environmental perspective, the small organisms that constitute the microbiome should be characterised as important building blocks for the greater biosphere, as they live in a symbiotic relationship with host organisms. 

“Simply put, if one wants to ensure both biodiversity and the ongoing vitality of larger species, it is critically important to understand the role that these organisms play.”

Newsletter Subscription

Stay informed of the latest news and features